Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 25;16(4):404-410.
doi: 10.1016/j.aju.2018.06.007. eCollection 2018 Dec.

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Diaa-Eldin Taha  1 , Omar M Aboumarzouk  2 , Ahmed A Shokeir  3
Affiliations
Review

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature

Diaa-Eldin Taha et al. Arab J Urol. .

Abstract

Objective: To evaluate the effect of oral desmopressin in patients with nocturia associated with benign prostatic hyperplasia (BPH).

Patients and methods: With a rise of the use of oral desmopressin in the treatment of nocturia in patients with BPH, a systematic review was performed according to the Cochrane systematic reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.

Results: The literature search yielded 18 studies. The studies were published between 1980 and 2017, and included 3072 patients. Eligible patients were men aged ≥50 years with lower urinary tract symptoms (LUTS) and persistent nocturia. There was a significant 43% reduction in nocturia after using desmopressin alone. Combined α-blockers and desmopressin lead to a decrease in the frequency of night voids by 64.3% compared to 44.6% when using α-blockers only. The first sleep period, significantly increased from 82.1 to 160.0 min and from 83.2 to 123.8 min when using desmopressin + α-blocker and α-blocker only, respectively. The desmopressin dose ranged from the lowest dose (0.05 mg) to the optimum dose (0.4 mg) at bed time. The incidence of hyponatraemia associated with desmopressin use was 4.4-5.7%.

Conclusion: Low-dose oral desmopressin therapy alone is an effective treatment for nocturia associated with LUTS in patients with BPH. Oral desmopressin combined with α-blockers is well tolerated and beneficial for improving the International Prostate Symptom Score and nocturnal symptoms. All patients should be educated about the mechanism of desmopressin action to avoid treatment discontinuation due to adverse events.

Keywords: AE, adverse event; FSP, first sleep period; ICIQ-N, International Consultation on Incontinence Questionnaire-Nocturia; ICS, International Continence Society; LUTS; NP, nocturnal polyuria; NPI, Nocturnal Polyuria Index; Nocturia; Nocturnal polyuria; Oral desmopressin; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PVR, post-void residual urine volume; RCT, randomised controlled trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of the article selection process for the review.
See this image and copyright information in PMC

References

    1. van Kerrebroeck P., Abrams P., Chaikin D., Donovan J., Fonda D., Jackson S. The standardisation of terminology in nocturia: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:179–183. - PubMed
    1. Yoong H.F., Sundaram M.B., Aida Z. Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia. Med J Malaysia. 2005;60:294–296. - PubMed
    1. Bae W.J., Bae J.H., Kim S.W., Chung B.H., Kim J.H., Kim C.S. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms. J Urol. 2013;190:180–186. - PubMed
    1. Yoshimura K., Ohara H., Ichioka K., Terada N., Matsui Y., Terai A. Nocturia and benign prostatic hyperplasia. Urology. 2003;61:786–790. - PubMed
    1. Weiss J.P., Blaivas J.G., Stember D.S., Brooks M.M. Nocturia in adults: etiology and classification. Neurourol Urodyn. 1998;17:467–472. - PubMed